Abstract
This issue reports two studies, one by Hatlen and colleagues and the other by Kim and colleagues, that detail the drug-development journey of the FGF19–FGFR4 inhibitor fisogatinib (BLU-554), from identification of the drug to preclinical validation studies to finally the results of the proof-of-concept first-in-human phase I trial of this potent and selective, type I irreversible inhibitor of FGFR4. Moreover, Hatlen and colleagues also report a resistance mechanism acquired after therapy that targets selective FGFR4 inhibition, which validates FGF as a specific target in hepatocellular cancer.
Original language | English (US) |
---|---|
Pages (from-to) | 1646-1649 |
Number of pages | 4 |
Journal | Cancer discovery |
Volume | 9 |
Issue number | 12 |
DOIs | |
State | Published - Dec 2019 |
ASJC Scopus subject areas
- Oncology